MedTrace Logo

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

NCT01235260 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2016-07-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Administration.

Conditions

Interventions

OTHER

Becaplermin nonusers

A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)

DRUG

Becaplermin users

A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)

Sponsors & Collaborators

  • Bedford Research Corporation, Inc.

    collaborator OTHER

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-03-31
Completion
2011-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01235260 on ClinicalTrials.gov